Back to Search
Start Over
Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Sep 22; Vol. 61 (10). Date of Electronic Publication: 2017 Sep 22 (Print Publication: 2017). - Publication Year :
- 2017
-
Abstract
- Linezolid serum trough ( C <subscript>min</subscript> ) and peak ( C <subscript>max</subscript> ) levels were determined prospectively in 90 patients. Adequate exposure was defined as a C <subscript>min</subscript> of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid C <subscript>min</subscript> levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.<br /> (Copyright © 2017 American Society for Microbiology.)
- Subjects :
- Aged
Anti-Bacterial Agents adverse effects
Female
Hospital Mortality
Humans
Linezolid adverse effects
Male
Middle Aged
Prospective Studies
Staphylococcal Infections mortality
Staphylococcus aureus drug effects
Treatment Outcome
Anti-Bacterial Agents blood
Anti-Bacterial Agents therapeutic use
Drug Monitoring
Linezolid blood
Linezolid therapeutic use
Staphylococcal Infections drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 61
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 28739788
- Full Text :
- https://doi.org/10.1128/AAC.00687-17